Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 234

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 15
Chunk 234
---
 quarter incidence levels of cough cold compared to the prior year, new business wins and store brand share gains amid lower consumption.

46

Perrigo Company plc - Item 2CSCA

CSCA net sales by product category were as follows:

SalesNine Months Ended(in millions, except percentages)September 27, 2025September 28, 2024$ Change% ChangeUpper Respiratory$390.4 $370.0 $20.3 5.5 %Digestive Health318.3 361.7 (43.4)(12.0)%Nutrition300.1 303.8 (3.7)(1.2)%Pain and Sleep-Aids245.4 251.9 (6.5)(2.6)%Healthy Lifestyle221.5 221.3 0.2 0.1 %Oral Care184.8 204.8 (20.2)(9.8)%Skin Care165.2 158.6 6.6 4.2 %Women's Health52.7 62.0 (9.2)(14.9)%VMS5.9 13.0 (7.1)(54.7)%Other CSCA4.0 2.4 1.8 66.7 %Total CSCA$1,888.3 $1,949.5 $(61.2)(3.1)%

Sales drivers in each category are provided below: 

•Upper Respiratory: Net sales of $390.4 million increased 5.5% due primarily to higher first quarter incidence levels of cough cold compared to the prior year, new business wins and store brand share gains amid lower consumption, leading to higher net sales of both cough and cold and allergy products, including store brand Fluticasone and Fexofenadine. This growth was partially offset by previously disclosed net lost distribution of lower margin products;

•Digestive Health: Net sales of $318.3 million decreased 12.0% due primarily to first half net lost distribution of lower margin products in U.S. Store Brand and lower consumption and customer mix of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo store brand share gains. These impacts more than offset higher net sales of Polyethylene Glycol, where Perrigo also gained store brand market share;

•Nutrition: Net